
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Click the title above to open the Pharmaceutical Executive March 2020 issue in an interactive PDF format.
.
over 6 years ago
The Multichannel Reach: Balancing the Local and Global Voiceover 6 years ago
Market Access: From Being to Becomingover 6 years ago
Consider Data Before It’s a Problemover 6 years ago
Multichannel Marketing: Integrating Omnichannelover 6 years ago
Feds Target Biosimilar Anticompetitive Practicesover 6 years ago
Blood Feud Divides Europe Over Plasma Shortfallsover 6 years ago
Social Media’s Influence in Messaging Mixover 6 years ago
Habib Bennaceur: Following the Scienceover 6 years ago
A Bad Deal with Data?over 6 years ago
Country Report: United Arab Emirates




